Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Haruki Kume, Kazuki Maki et al.|Japanese Journal of Clinical Oncology|2025Cited by 7
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Haruki Kume, Taketo Kawai et al.|International Journal of Clinical Oncology|2025Cited by 3